Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
Thu, 31
Oct
2024
Posted by: Biocon Biologics
The future of a sustainable biosimilars market in the US depends on strategic legislative reforms, improved education for stakeholders, and a robust reimbursement framework that together enhance accessibility, build confidence, and ensure long-term cost savings in health care, according to a panel of industry leaders.1
With $36 billion saved in 2023 and nearly 3 billion days of patient therapy delivered without any clinically significant differences from originator biologics, biosimilars are proving their value in the health care space. The panel discussion took place at the GRx+Biosims 2024 conference and included representatives from 3 biosimilar manufacturers (Sandoz, Teva Pharmaceuticals, Biocon Biologics).
Author:
Biocon Biologics
Biocon Biologics